Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 199

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 199
---
1 million subject to the following achievements: submission
of investigational new drug application; completion of phase 1, 2 and 3 clinical trials; and submission of new drug application; grant
of regulatory approval. We also agreed to pay to the licensor aggregate sales milestones of up to US$7.8 million subject to the following
achievement: first commercial sale; and annual net sales exceeding US$100 million in one jurisdiction.

Pursuant to the license agreements,
Acticule became the exclusive licensee of 2 pending U.S. non-provisional patent applications and 2 PCT applications (now expired). Prior
to the expiration of the PCT applications, we filed national phase applications in member states of the EPO, in PRC and 12 other jurisdictions.
The claimed inventions are described as: “Compounds Affecting Pigment Production and Methods for Treatment of Bacterial Diseases.”

Four (4) US patents and two
(2) Israeli patents have been granted by the United States Patent and Trademark Office and the Israel Patent office respectively.

Acticule has the right to
grant sublicenses to third parties under the license agreements without prior approval from Versitech Limited and to assign the agreements
to any successor to the business related to the licenses. In the event that Acticule makes an improvement to the licensed technologies,
so long as the improvement does not incorporate any licensed patents, Acticule will be the owner to such improvement, subject to a non-exclusive
royalty-free license being granted back to Versitech Limited for academic and research purposes only.

The exclusive license agreements
shall be in effect until the expiration of all licensed patents (please refer to the patent expiration dates under “Intellectual
Property”). Acticule may terminate the licenses at any time with 6-month written notice in advance. Either party may terminate the
agreements upon a material breach by other party.

SACT-1: A Repurposed Drug for the Treatment of Neuroblastoma

Drug repurposing is a strategy
for identifying new indications for approved or investigational drugs that are outside the scope of the original medical uses. It is often
viewed as a lower-cost method for drug commercialization, as it is based on already-approved drugs (which has been proven to be safe for
human use by the respective governing regulatory agency) and explores new target indications. (Ashburn, T. T. & Thor, K. B. Drug repositioning:
identifying and developing new uses for existing